Cargando…

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials

Objective To determine how length of anticoagulation and clinical presentation of venous thromboembolism influence the risk of recurrence after anticoagulant treatment is stopped and to identify the shortest length of anticoagulation that reduces the risk of recurrence to its lowest level. Design Po...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutitie, Florent, Pinede, Laurent, Schulman, Sam, Agnelli, Giancarlo, Raskob, Gary, Julian, Jim, Hirsh, Jack, Kearon, Clive
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100759/
https://www.ncbi.nlm.nih.gov/pubmed/21610040
http://dx.doi.org/10.1136/bmj.d3036
_version_ 1782204210329157632
author Boutitie, Florent
Pinede, Laurent
Schulman, Sam
Agnelli, Giancarlo
Raskob, Gary
Julian, Jim
Hirsh, Jack
Kearon, Clive
author_facet Boutitie, Florent
Pinede, Laurent
Schulman, Sam
Agnelli, Giancarlo
Raskob, Gary
Julian, Jim
Hirsh, Jack
Kearon, Clive
author_sort Boutitie, Florent
collection PubMed
description Objective To determine how length of anticoagulation and clinical presentation of venous thromboembolism influence the risk of recurrence after anticoagulant treatment is stopped and to identify the shortest length of anticoagulation that reduces the risk of recurrence to its lowest level. Design Pooled analysis of individual participants’ data from seven randomised trials. Setting Outpatient anticoagulant clinics in academic centres. Population 2925 men or women with a first venous thromboembolism who did not have cancer and received different durations of anticoagulant treatment. Main outcome measure First recurrent venous thromboembolism after stopping anticoagulant treatment during up to 24 months of follow-up. Results Recurrence was lower after isolated distal deep vein thrombosis than after proximal deep vein thrombosis (hazard ratio 0.49, 95% confidence interval 0.34 to 0.71), similar after pulmonary embolism and proximal deep vein thrombosis (1.19, 0.87 to 1.63), and lower after thrombosis provoked by a temporary risk factor than after unprovoked thrombosis (0.55, 0.41 to 0.74). Recurrence was higher if anticoagulation was stopped at 1.0 or 1.5 months compared with at 3 months or later (hazard ratio 1.52, 1.14 to 2.02) and similar if treatment was stopped at 3 months compared with at 6 months or later (1.19, 0.86 to 1.65). High rates of recurrence associated with shorter durations of anticoagulation were confined to the first 6 months after stopping treatment. Conclusion Three months of treatment achieves a similar risk of recurrent venous thromboembolism after stopping anticoagulation to a longer course of treatment. Unprovoked proximal deep vein thrombosis and pulmonary embolism have a high risk of recurrence whenever treatment is stopped.
format Text
id pubmed-3100759
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-31007592011-06-01 Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials Boutitie, Florent Pinede, Laurent Schulman, Sam Agnelli, Giancarlo Raskob, Gary Julian, Jim Hirsh, Jack Kearon, Clive BMJ Research Objective To determine how length of anticoagulation and clinical presentation of venous thromboembolism influence the risk of recurrence after anticoagulant treatment is stopped and to identify the shortest length of anticoagulation that reduces the risk of recurrence to its lowest level. Design Pooled analysis of individual participants’ data from seven randomised trials. Setting Outpatient anticoagulant clinics in academic centres. Population 2925 men or women with a first venous thromboembolism who did not have cancer and received different durations of anticoagulant treatment. Main outcome measure First recurrent venous thromboembolism after stopping anticoagulant treatment during up to 24 months of follow-up. Results Recurrence was lower after isolated distal deep vein thrombosis than after proximal deep vein thrombosis (hazard ratio 0.49, 95% confidence interval 0.34 to 0.71), similar after pulmonary embolism and proximal deep vein thrombosis (1.19, 0.87 to 1.63), and lower after thrombosis provoked by a temporary risk factor than after unprovoked thrombosis (0.55, 0.41 to 0.74). Recurrence was higher if anticoagulation was stopped at 1.0 or 1.5 months compared with at 3 months or later (hazard ratio 1.52, 1.14 to 2.02) and similar if treatment was stopped at 3 months compared with at 6 months or later (1.19, 0.86 to 1.65). High rates of recurrence associated with shorter durations of anticoagulation were confined to the first 6 months after stopping treatment. Conclusion Three months of treatment achieves a similar risk of recurrent venous thromboembolism after stopping anticoagulation to a longer course of treatment. Unprovoked proximal deep vein thrombosis and pulmonary embolism have a high risk of recurrence whenever treatment is stopped. BMJ Publishing Group Ltd. 2011-05-24 /pmc/articles/PMC3100759/ /pubmed/21610040 http://dx.doi.org/10.1136/bmj.d3036 Text en © Boutitie et al 2011 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Research
Boutitie, Florent
Pinede, Laurent
Schulman, Sam
Agnelli, Giancarlo
Raskob, Gary
Julian, Jim
Hirsh, Jack
Kearon, Clive
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials
title Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials
title_full Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials
title_fullStr Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials
title_full_unstemmed Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials
title_short Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials
title_sort influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100759/
https://www.ncbi.nlm.nih.gov/pubmed/21610040
http://dx.doi.org/10.1136/bmj.d3036
work_keys_str_mv AT boutitieflorent influenceofprecedinglengthofanticoagulanttreatmentandinitialpresentationofvenousthromboembolismonriskofrecurrenceafterstoppingtreatmentanalysisofindividualparticipantsdatafromseventrials
AT pinedelaurent influenceofprecedinglengthofanticoagulanttreatmentandinitialpresentationofvenousthromboembolismonriskofrecurrenceafterstoppingtreatmentanalysisofindividualparticipantsdatafromseventrials
AT schulmansam influenceofprecedinglengthofanticoagulanttreatmentandinitialpresentationofvenousthromboembolismonriskofrecurrenceafterstoppingtreatmentanalysisofindividualparticipantsdatafromseventrials
AT agnelligiancarlo influenceofprecedinglengthofanticoagulanttreatmentandinitialpresentationofvenousthromboembolismonriskofrecurrenceafterstoppingtreatmentanalysisofindividualparticipantsdatafromseventrials
AT raskobgary influenceofprecedinglengthofanticoagulanttreatmentandinitialpresentationofvenousthromboembolismonriskofrecurrenceafterstoppingtreatmentanalysisofindividualparticipantsdatafromseventrials
AT julianjim influenceofprecedinglengthofanticoagulanttreatmentandinitialpresentationofvenousthromboembolismonriskofrecurrenceafterstoppingtreatmentanalysisofindividualparticipantsdatafromseventrials
AT hirshjack influenceofprecedinglengthofanticoagulanttreatmentandinitialpresentationofvenousthromboembolismonriskofrecurrenceafterstoppingtreatmentanalysisofindividualparticipantsdatafromseventrials
AT kearonclive influenceofprecedinglengthofanticoagulanttreatmentandinitialpresentationofvenousthromboembolismonriskofrecurrenceafterstoppingtreatmentanalysisofindividualparticipantsdatafromseventrials